Literature DB >> 22154771

Lactococcus lactis-based vaccines from laboratory bench to human use: an overview.

Mohammed Bahey-El-Din1.   

Abstract

Developing effective vaccines is an important weapon in the battle against potential pathogens and their evolving antibiotic resistance trends. Several vaccine delivery vectors have been investigated among which the generally regarded as safe (GRAS) Lactococcus lactis has a distinguished position. In this review, different factors affecting the efficacy of L. lactis-based vaccines are discussed. In addition, the issues of biological containment and pharmaceutical quality assurance of L. lactis vaccines are highlighted. These issues are critical for the success of medical translation of L. lactis-based vaccines from research laboratories to clinical use by ensuring consistent manufacturing of safe and efficacious vaccines.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22154771     DOI: 10.1016/j.vaccine.2011.11.098

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

1.  Development of Lactococcus lactis encoding fluorescent proteins, GFP, mCherry and iRFP regulated by the nisin-controlled gene expression system.

Authors:  E Martinez-Jaramillo; R Garza-Morales; M J Loera-Arias; O Saucedo-Cardenas; R Montes-de-Oca-Luna; L R McNally; J G Gomez-Gutierrez
Journal:  Biotech Histochem       Date:  2017-03-20       Impact factor: 1.718

2.  Recombinant Lactococcus Lactis Displaying Omp31 Antigen of Brucella melitensis Can Induce an Immunogenic Response in BALB/c Mice.

Authors:  Hoda Shirdast; Fatemeh Ebrahimzadeh; Amir Hossein Taromchi; Yousef Mortazavi; Abdolreza Esmaeilzadeh; Mohammad Hadi Sekhavati; Keivan Nedaei; Esmat Mirabzadeh
Journal:  Probiotics Antimicrob Proteins       Date:  2021-02       Impact factor: 4.609

3.  Oral Immunization with a Recombinant Lactococcus lactis-Expressing HIV-1 Antigen on Group A Streptococcus Pilus Induces Strong Mucosal Immunity in the Gut.

Authors:  Venkateswarlu Chamcha; Andrew Jones; Bernard R Quigley; June R Scott; Rama Rao Amara
Journal:  J Immunol       Date:  2015-10-19       Impact factor: 5.422

4.  Surface Display of Heterologous β-Galactosidase in Food-Grade Recombinant Lactococcus lactis.

Authors:  Supeng Yin; Hongbin Zhu; Mengyu Shen; Gang Li; Shuguang Lu; Yan Zhao; Shuai Le; Yinling Tan; Yizhi Peng; Fuquan Hu; Jing Wang
Journal:  Curr Microbiol       Date:  2018-06-19       Impact factor: 2.188

5.  Improvement of LysM-mediated surface display of designed ankyrin repeat proteins (DARPins) in recombinant and nonrecombinant strains of Lactococcus lactis and Lactobacillus Species.

Authors:  Petra Zadravec; Borut Štrukelj; Aleš Berlec
Journal:  Appl Environ Microbiol       Date:  2015-01-09       Impact factor: 4.792

6.  Method for Production of Cysteine-Rich Proteins in Lactococcus lactis Expression System.

Authors:  Susheel K Singh; Vandana Singh
Journal:  Methods Mol Biol       Date:  2022

7.  Two-tiered biological containment strategy for Lactococcus lactis-based vaccine or immunotherapy vectors.

Authors:  Aurelie Hanin; Eamonn P Culligan; Pat G Casey; Mohammed Bahey-El-Din; Colin Hill; Cormac G M Gahan
Journal:  Hum Vaccin Immunother       Date:  2013-11-06       Impact factor: 3.452

Review 8.  Probiotic-Based Vaccines May Provide Effective Protection against COVID-19 Acute Respiratory Disease.

Authors:  Sedigheh Taghinezhad-S; Amir Hossein Mohseni; Luis G Bermúdez-Humarán; Vincenzo Casolaro; Naima G Cortes-Perez; Hossein Keyvani; Jesus Simal-Gandara
Journal:  Vaccines (Basel)       Date:  2021-05-06

9.  Protective Immunity Against Enterotoxigenic Escherichia coli by Oral Vaccination of Engineered Lactococcus lactis.

Authors:  Homa Ahmadi Rouzbahani; Seyed Latif Mousavi Gargari; Shahram Nazarian; Sajad Abdollahi
Journal:  Curr Microbiol       Date:  2021-07-15       Impact factor: 2.188

Review 10.  Novel vaccine strategies against emerging viruses.

Authors:  Adolfo García-Sastre; Ignacio Mena
Journal:  Curr Opin Virol       Date:  2013-03-07       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.